Perspective Therapeutics, INC 8-K filings

Perspective Therapeutics updates its corporate presentation, emphasizing its radiopharmaceutical therapy platform and ongoing clinical trials.

Perspective Therapeutics has dosed the first patient in a Phase 1/2a trial evaluating the safety and anti-tumor activity of [212Pb]PSV359 in patients with solid tumors expressing fibroblast activation protein alpha (FAP).

Perspective Therapeutics has dosed the first patient in a new cohort of its Phase 1/2a trial evaluating [212Pb]VMT01 as a monotherapy for melanoma.

Perspective Therapeutics announces its full year 2024 financial results, highlighting clinical progress and manufacturing expansion.

Perspective Therapeutics has dosed the first patient in a Phase 1/2a trial combining [212Pb]VMT01 with nivolumab for metastatic melanoma.

Perspective Therapeutics updates its corporate presentation, emphasizing its radiopharmaceutical therapy platform and clinical trial progress.

Perspective Therapeutics provides a corporate update, highlighting clinical pipeline advancements, a strong intellectual property portfolio, and a solid financial position with funding into late 2026.

Perspective Therapeutics reported updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT--NET, showing a favorable safety profile and encouraging anti-tumor activity in patients with neuroendocrine tumors.

Perspective Therapeutics has announced strategic priorities, clinical updates, and preliminary unaudited financials, projecting sufficient cash to fund operations into late 2026.

Perspective Therapeutics has appointed Juan Graham as its new Chief Financial Officer, effective January 6, 2025, while Jonathan Hunt transitions to Chief Accounting Officer.

Perspective Therapeutics has released an updated corporate presentation detailing its clinical programs, proprietary technology, and financial position.

Perspective Therapeutics reported encouraging initial safety and efficacy data from its Phase 1/2a clinical trial of [212Pb]VMT--NET, showing durable disease control and tumor reduction in a majority of patients with neuroendocrine tumors.

Perspective Therapeutics has released an updated corporate presentation, showcasing its clinical pipeline, proprietary technology, and financial strength.

Perspective Therapeutics announced its third quarter financial results for 2024, along with updates on its clinical programs and manufacturing expansion.

Perspective Therapeutics reports positive initial findings from its Phase 1/2a study of [212Pb]VMT01 for metastatic melanoma, showing safety and encouraging efficacy signals.

Perspective Therapeutics has entered into a $49 million agreement with Comecer SpA to purchase manufacturing equipment for radiopharmaceutical production.

Perspective Therapeutics has been granted Fast Track Designation by the FDA for its 212Pb VMT01 therapy targeting MC1R-positive melanoma.

Perspective Therapeutics has entered into a separation agreement with former co-principal financial officer Mark Austin, who will transition to a strategic advisor role before his final departure.

Perspective Therapeutics has announced that Mark Austin has stepped down from his role as Vice President of Finance, with Jonathan Hunt becoming the sole principal financial officer and principal accounting officer, effective August 16, 2024.

Perspective Therapeutics has entered into an agreement to sell up to $250 million of its common stock through an at-the-market offering.

Perspective Therapeutics has released an updated corporate presentation detailing its clinical pipeline, financial position, and strategic outlook, emphasizing its targeted alpha therapy platform.

Perspective Therapeutics announced its second quarter 2024 financial results, highlighting clinical trial progress and manufacturing infrastructure development.

Perspective Therapeutics announced its first quarter 2024 financial results, along with updates on clinical trials, new technology in-licensing, and a significant capital raise.

Perspective Therapeutics has completed a 1-for-10 reverse stock split of its common stock, effective June 14, 2024, to increase its share price.

Perspective Therapeutics' shareholders approved an increase in shares for the equity incentive plan and a reverse stock split at the 2024 Annual Meeting.

Perspective Therapeutics has announced the pricing of an underwritten offering expected to generate approximately $80 million in gross proceeds through the sale of common stock and pre-funded warrants.

Perspective Therapeutics will present data on its cancer therapies, including VMT-NET and other promising treatments, at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting in June.

Perspective Therapeutics announced its first quarter 2024 financial results, along with key clinical and platform developments, including progress in clinical trials and new technology in-licensing.

Perspective Therapeutics has completed the sale of its Isoray Medical subsidiary's assets to GT Medical Technologies, receiving stock and future royalty payments.

Perspective Therapeutics has changed its independent registered public accounting firm from Assure CPA to WithumSmith+Brown, effective immediately on April 5, 2024.